# Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

> **NCT00701103** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 80 (actual)

## Conditions studied

- Solid Tumor
- Multiple Myeloma

## Interventions

- **DRUG:** Dalotuzumab

## Key facts

- **NCT ID:** NCT00701103
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-12
- **Primary completion:** 2009-12-01
- **Final completion:** 2009-12-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00701103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00701103, "Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00701103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*